Appendix 4C - quarterly
Filed with ASX · · 8 pages · English
CLINUVEL PHARMACEUTICALS LTD today announced its Appendix 4C–Quarterly Cashflow Report and Activity Report for the period 01 January to 31 March 2021. All figures are rounded and reported in Australian dollars. CLINUVEL MAINTAINS FOCUS The coronavirus pandemic continues to have an adverse impact KEY CASH FLOW HIGHLIGHTS Q3 FY21 on healthcare services, chronically ill patients and the operating env
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Media Release - CLINUVEL expands DNA Repair Program
- Appendix 4D Half Yearly Report
- CLINUVEL Strategic Update - Extended
- Media Release - CLINUVEL to Trial Innovative Drug in Stroke
- Australian TGA approves SCENESSE
Later from Clinuvel Pharmaceuticals
- Appendix 4E and Preliminary Financial Report
- CLINUVEL Delivers Record Revenues and Profit
- Response to ASX Price Query
- Appendix 4D Half Year Report
- CLINUVEL Reports December Half Year Operating Results
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals